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Chronic pulmonary aspergillosis (CPA) is a recognized 
complication of pulmonary tuberculosis (TB). In 2015, the 
World Health Organization reported 2.2 million new cases 
of nonbacteriologically confirmed pulmonary TB; some of 
these patients probably had undiagnosed CPA. In October 
2016, the Global Action Fund for Fungal Infections con-
vened an international expert panel to develop a case defi-
nition of CPA for resource-constrained settings. This panel 
defined CPA as illness for >3 months and all of the follow-
ing: 1) weight loss, persistent cough, and/or hemoptysis; 2) 
chest images showing progressive cavitary infiltrates and/or 
a fungal ball and/or pericavitary fibrosis or infiltrates or pleu-
ral thickening; and 3) a positive Aspergillus IgG assay result 
or other evidence of Aspergillus infection. The proposed 
definition will facilitate advancements in research, practice, 
and policy in lower- and middle-income countries as well as 
in resource-constrained settings.
The differential diagnosis for pulmonary tuberculosis (TB) is wide and includes nontuberculous mycobac-
teria (NTM) infection, endemic fungal infections such as 
coccidioidomycosis and histoplasmosis, allergic broncho-
pulmonary aspergillosis, and chronic pulmonary asper-
gillosis (CPA) (1–7). Sequelae of pulmonary TB, such as 
bronchiectasis and restricted lung capacity, can mimic in-
fection relapse (8–10). Accurate diagnosis is essential for 
adequate treatment.
The 2015 World Health Organization annual report 
notes that ≈2.2 million (≈43%) of 5.2 million cases of in-
cident pulmonary TB were clinically diagnosed or smear-
negative (11). Only 21%–40% of smear-negative pulmo-
nary TB cases are culture positive (12,13). Exclusion of 
alternatives is challenging in many lower- and middle-in-
come countries (14). The World Health Organization report 
comments, “Most clinical features of TB and abnormalities 
on X-ray or histology results generally associated with TB 
have low specificity, which may lead to false diagnoses of 
TB, and hence to people being enrolled on TB treatment 
unnecessarily” (11).
Case Definition of Chronic Pulmonary  
Aspergillosis in Resource-Constrained Settings
David W. Denning, Iain D. Page, Jeremiah Chakaya, Kauser Jabeen, Cecilia M. Jude,  
Muriel Cornet, Ana Alastruey-Izquierdo, Felix Bongomin, Paul Bowyer, Arunaloke Chakrabarti,  
Sara Gago, John Guto, Bruno Hochhegger, Martin Hoenigl, Muhammad Irfan, Nicholas Irurhe,  
Koichi Izumikawa, Bruce Kirenga, Veronica Manduku, Samihah Moazam, Rita O. Oladele,  
Malcolm D. Richardson, Juan Luis Rodriguez Tudela, Anna Rozaliyani, Helmut J.F. Salzer,  
Richard Sawyer, Nasilele F. Simukulwa, Alena Skrahina, Charlotte Sriruttan,  
Findra Setianingrum, Bayu A.P. Wilopo, Donald C. Cole, Haileyesus Getahun
e1 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 8, August 2018
ONLINE REPORT
Author affiliations: University of Manchester, Manchester, UK  
(D.W. Denning, I.D. Page, F. Bongomin, P. Bowyer, S. Gago,  
R.O. Oladele, C. Sriruttan, F. Setianingrum, B.A.P. Wilopo);  
Wythenshawe Hospital Manchester University NHS Foundation 
Trust, Manchester (D.W. Denning, I.D. Page, S. Moazam,  
M.D. Richardson, R. Sawyer); The Global Action Fund for  
Fungal Infections, Geneva, Switzerland (D.W. Denning, J. Guto, 
J.L. Rodriguez Tudela); Kenya Medical Research Institute,  
Nairobi, Kenya (J. Chakaya, V. Manduku); Aga Khan University, 
Karachi, Pakistan (K. Jabeen, M. Irfan); Olive View–UCLA  
Medical Center, Sylmar, California, USA (C.M. Jude); Centre  
Hospitalier Universitaire Grenoble Alpes, Grenoble, France  
(M. Cornet); Instituto de Salud Carlos III, Madrid, Spain  
(A. Alastruey-Izquierdo); Postgraduate Institute of Medical  
Education and Research, Chandigarh, India (A. Chakrabarti); 
Federal University of Health Sciences of Porto Alegre, Porto 
Alegre, Brazil (B. Hochhegger); University of California San  
Diego, San Diego, California, USA (M. Hoenigl); Medical  
University of Graz, Graz, Austria (M. Hoenigl); Center for  
Biomarker Research in Medicine, Graz (M. Hoenigl); Lagos  
University Teaching Hospital, Lagos, Nigeria (N. Irurhe);  
Nagasaki University Graduate School of Biomedical  
Sciences, Nagasaki, Japan (K. Izumikawa); Mulago Hospital  
and Makerere University, Kampala, Uganda (B. Kirenga);  
University of Lagos, Lagos (R.O. Oladele); Universitas Indonesia,  
Jakarta, Indonesia (A. Rozaliyani, F. Setianingrum); Research 
Center Borstel, Borstel, Germany (H.J.F. Salzer); Royal  
Liverpool University Hospital, Liverpool, UK (N.F. Simukulwa);  
The Republican Scientific and Practical Centre for  
Pulmonology and TB, Minsk, Belarus (A. Skrahina, C. Sriruttan); 
National Institute for Communicable Diseases, Johannesburg, 
South Africa (C. Sriruttan); University of the Witwatersrand,  
Johannesburg (C. Sriruttan); Universitas Padjadjaran, Bandung, 
Indonesia (B.A.P. Wilopo); University of Toronto, Toronto,  
Ontario, Canada (D.C. Cole); World Health Organization,  
Geneva (H. Getahun)
DOI: https://doi.org/10.3201/eid2408.171312
ONLINE REPORT
Although coccidioidomycosis, histoplasmosis, and 
paracoccidioidomycosis are regionally confined, aspergillosis 
is global. Each year, an estimated 373,000 new CPA cases 
complicate treated pulmonary TB within 12 months of 
completion of anti-TB therapy; the 5-year period prevalence 
is 1,174,000 (range 397,000–2,088,000) cases (9). This wide 
range results from several factors, notably the extrapolation 
of CPA diagnosis from a limited UK dataset of only 544 
patients with pulmonary cavities (15), substantial variability 
in the published frequency of cavitation after treatment of 
pulmonary TB, absence of an estimate of CPA prevalence 
among patients without cavities, and lack of knowledge 
of the effects of concurrent HIV infection. The incidence 
and prevalence of CPA are not known but are probably 
underestimated, in part because CPA occurs in patients 
with active pulmonary TB, as a sequela of prior pulmonary 
TB (16), or as a complication of other pulmonary disorders 
with symptoms similar to those of pulmonary TB, and is 
incorrectly diagnosed and treated as pulmonary TB (17).
Diagnostic guidelines for CPA have recently been 
published in English and Japanese, emphasizing the central 
role of advanced imaging and serologic testing for Aspergillus 
(18–20). Unfortunately, these diagnostics are infrequently 
available in many resource-constrained settings. In October 
2016, the Global Action Fund for Fungal Infections 
convened an international panel to develop an operational 
definition of CPA for research and clinical care in resource-
constrained settings. The panel’s goals were to adapt the 
existing European Society for Clinical Microbiology and 
Infectious Diseases and European Respiratory Society (19) 
and Infectious Diseases Society of America guideline case 
definitions of CPA (18) to promote research so that critical 
data will be available to inform policy and practice, including 
surveillance, and to enable individualized clinical care for 
optimal patient management.
Methods
Literature and Existing Guidelines
We built on the work of 2 recent CPA expert panels (18–
20). These panels undertook comprehensive searching, ap-
praisal, and synthesis of the relevant literature, including 
diagnosis and case definitions. We included these papers 
in a package of materials relevant to diagnosis in differ-
ent clinical contexts (i.e., underlying disease in patients in 
whom CPA is developing, CPA and clinically diagnosed 
pulmonary TB, radiologic assessment and characteristics 
of CPA, and comparisons of laboratory diagnosis with dif-
ferent immunoassays).
Workshop Participants
The Global Action Fund for Fungal Infections 
(https://www.gaffi.org) invited 36 experts from all regions 
of the world, according to expertise. The experts had 
already implemented CPA diagnostic capacity or were in 
the process of doing so. Participants also included experts 
from lower- and middle-income countries that had active 
clinical and public health programs focused on respiratory 
diseases including TB. Clinical expertise included 
internal medicine, pulmonary disease, infectious disease, 
critical care, thoracic radiology, medical microbiology, 
and medical mycology, as well as various health system 
organizational roles and levels (e.g., secondary care 
consultants, national reference laboratories, national 
research centers, and international health organizations). 
Of the 36 invited experts, 33 (the authors) attended a 
workshop in Liverpool, UK.
Operational Definitions Indicator Selection
Morning presentations and discussions built on prior read-
ing material and provided all participants evidence of CPA 
burden, risk factors, clinical presentations, diagnostic tools, 
treatment options, recurrences, and prior case definitions. 
Three facilitated afternoon breakout groups started with 
CPA diagnostic indicator types (i.e., clinical presentation, 
radiology, medical microbiology–mycology–immunology) 
and discussed options for diagnosis, focusing on second-
ary care levels and above for lower- and middle-income 
countries. A recorder took notes, and the pros and cons of 
different indicators were shared in a plenary session. Sub-
sequently, 3 cross-indicator groups worked to bring the in-
dicators together, constructing key criteria for CPA with 
different clinical or radiologic presentations.
Development of Case Definitions 
Plenary discussion participants compared and contrasted 
the different approaches and moved toward operation-
al definitions. On the basis of consolidated notes from 
breakout groups and plenary sessions, descriptions of 
possible, probable, and confirmed CPA were synthe-
sized to garner consensus on the most critical elements 
of the diagnosis. Simple graphic representations were 
developed, shared with breakout group leaders for feed-
back, and subsequently revised through iteration. Fur-
ther iteration on the key elements of the algorithms to be 
used in the field and minimal definitional requirements 
were conducted via email and online file-sharing ser-
vices, simplifying the definition to a single, composite 
definition and algorithm.
Results
Modern diagnostic criteria for CPA date from 2003 (21) 
and have been used in some prospective clinical trials 
(Table 1) and refined for specific purposes. The consensus 
group considered diagnostic criteria in 3 sections: clinical 
features, radiologic criteria, and microbiological criteria.
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Table 1. Published diagnostic features and criteria for chronic pulmonary aspergillosis* 
Parameter 
Reference 
(21) (22) (23) (24)† (25) (19) 
Symptoms >1 of the following 
for 3 mo: WL, 
productive cough, 
hemoptysis plus 
absence of overt 
immunosuppression 
>1 of the 
following (no 
duration 
specified): fever, 
WL, sputum 
production, 
cough, 
hemoptysis, 
fatigue, 
shortness of 
breath 
Performance 
status 1–2 
All of the 
following 
required for 1–6 
mo: fever, 
cough, sputum 
production, 
weight loss 
>1 of the following 
for 3 mo: weight 
loss, productive 
cough, hemoptysis 
plus absence of 
overt 
immunosuppression 
“Significant pulmonary 
and/or systemic 
symptoms for 3 
months or more”; no 
specific symptoms 
listed 
Radiology >1 of the following: 
cavitary lesion with 
paracavitary 
fibrosis, new or 
expanding cavity on 
serial imaging 
>1 of the 
following: new 
infiltrates, cavity 
formation, 
expansion of 
preexisting 
cavities; with or 
without the 
following: 
pericavitary 
infiltrates, 
adjacent pleural 
thickening 
Compatible 
chest CT scan 
or photo-
graphically 
confirmed 
endoscopic 
lesion 
Cavitary 
pulmonary 
lesion with 
evidence of 
pericavitary 
infiltrates and 
adjacent pleural 
thickening 
with/without 
fungal ball 
>1 of the following: 
cavitary lesion with 
paracavitary 
fibrosis, new or 
expanding cavity on 
serial imaging 
Both required: >1 
pulmonary cavities 
with either thick or thin 
wall, possibly 
containing 
aspergilloma or 
irregular intraluminal 
material; overt 
radiologic progression 
over >3 mo required 
(new cavities, 
increasing pericavitary 
infiltrates, or 
increasing fibrosis) 
Aspergillus 
antibody/ 
culture 
Either positive 
precipitins, or, 
culture from 
pulmonary or 
pleural cavity 
>1 of the 
following: 
platelia serum 
galactomannan 
index >1.0, 
positive 
precipitins, 
positive (1,3)--
D-glucan, 
evidence of 
Aspergillus spp. 
by molecular 
diagnosis, 
culture or 
pathological 
findings 
Positive 
serologic test 
required by both 
of the following: 
precipitins by 
CIE with >2 
lines, second 
serologic test 
positive by any 
method; and 
microbiological 
evidence by 1 of 
the following 
sources from 
BAL or sputum 
samples: >2 or 
more positive 
cultures, 1 
positive culture 
and positive 
microscopy 
Culture from 
sputum or BAL 
mandatory, 
antibodies not 
required 
Either raised 
Aspergillus-specific 
IgG or culture from 
pulmonary or 
pleural cavity 
If fungal ball present: 
Aspergillus-
IgG/precipitins or other 
evidence of 
Aspergillus. If no 
fungal ball but >1 
cavities, then any of 
the following: 
Aspergillus-specific 
IgG, Aspergillus 
precipitins, strongly 
positive Aspergillus 
antigen or DNA in 
respiratory fluids, 
percutaneous or 
excision biopsy 
showing fungal 
hyphae on 
microscopy, growing 
Aspergillus from a 
cavity. These tests on 
respiratory samples 
not sufficient in 
isolation: culture, 
PCR, microscopy 
Inflammatory 
markers 
Raised levels of 
either: CRP, ESR, 
plasma viscosity 
>1 of the 
following raised: 
leukocyte count, 
CRP, ESR 
Not required Not required Raised levels of 
either: CRP, ESR 
Not required 
Exclusion of 
other 
pathogens 
Required with the 
following examples: 
mycobacteria, 
endemic mycoses 
Lack of 
improvement 
with >3 d of 
broad-spectrum 
antimicrobial 
drugs required; 
patients with 
infectious 
diseases  
other than 
aspergillosis 
excluded 
Not required Required with 
the following 
examples: TB, 
other mycoses, 
granulomatosis 
with polyangiitis, 
ABPA, invasive 
aspergillosis, 
simple 
aspergilloma† 
Not specifically 
required 
Required with the 
following examples: 
TB, atypical 
mycobacteria, 
necrotizing lung 
cancer, pulmonary 
infarction, vasculitides, 
rheumatoid nodule, 
histoplasmosis/ 
coccidioidomycosis/ 
paracoccidioido-
mycosis in those with 
relevant travel history 
*ABPA, allergic bronchopulmonary aspergillosis; BAL, bronchoalveolar lavage; CIE, counterimmunoelectrophoresis; CNPA, chronic necrotizing pulmonary 
aspergillosis; CRP, C-reactive protein: CT, computed tomography; ESR, erythrocyte sedimentation rate; TB, tuberculosis; WL, weight loss. 
†This definition includes CNPA cases with 1–3 mo symptoms. Note: precipitins sensitivity even lower than culture. Pleural thickening seems to be a 
mandatory criterion. 
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Clinical Features
Underlying Diseases
Most CPA patients have prior or concurrent underlying 
pulmonary disease. Possible risk factors for development 
of CPA are cavities in the lung caused by pulmonary TB, 
sarcoidosis, previous Pneumocystis pneumonia, bullae or 
lung cysts, lung abscess, pulmonary infarction, pulmonary 
fibrosis, healed abscess cavities, cavitary bronchogenic 
carcinoma, and infection by NTM (21,26–30). In many 
countries, pulmonary TB is the most common disorder that 
precedes CPA (9). The most common differential diagnosis 
is pulmonary mycobacterial infection.
Duration
The duration of disease required to define CPA used by 
previous studies has been 1–6 months, usually 3 months. 
(Table 1). The expert panel consensus was to endorse a 
3-month duration as a criterion for diagnosis of CPA. In 
patients with preexisting pulmonary disease, who often 
have chronic signs and symptoms, a change in pattern or 
severity of clinical presentation is considered the trigger 
point for the 3-month duration. In patients with few or 
unchanged signs and symptoms, documentation of 3-month 
duration may also be confirmed with radiographic findings 
of progression of cavitation, pericavitary infiltrates or 
fibrosis, development of a fungal ball (which takes weeks 
to form), or microbiological data.
Signs and Symptoms
Most patients with CPA experience clinical signs and 
symptoms, although some are asymptomatic and show 
progression radiologically only. The most distinctive and 
alarming sign is hemoptysis/hemosputum. Hemoptysis 
develops in ≈12%–43% of CPA patients (23,25,31,32) and 
varies from blood streaking in sputum to massive and fatal 
hemoptysis. Hemoptysis may occur in patients with TB, 
but it is only streaking of sputum with blood and usually 
not severe. Another characteristic symptom is mild but 
persistent chest pain, discomfort, or tightness, experienced 
by up to 37% of patients. Weight loss and fatigue are 
also common, although not universal. Cough (usually 
productive) and dyspnea are common but not sufficiently 
distinctive to distinguish CPA from other pulmonary 
disorders, including pulmonary TB. Fever or pyrexia is 
uncommon in CPA patients and, if present, may indicate 
a concurrent or alternative diagnosis or subacute invasive 
aspergillosis. Night or day sweats are occasionally reported 
but are not discriminatory.
The consensus of the panel was that the diagnosis of 
CPA required the presence of >1 symptoms persisting for 
3 months and radiologic progression, a scenario present 
in most cases. Two other clinical scenarios that also 
qualify for the diagnosis of CPA are radiologic evidence 
of a simple aspergilloma (with or without symptoms) and 
characteristic radiologic appearance without symptoms but 
showing definite radiologic progression.
Radiologic Criteria
The focus of the discussion revolved around use of chest 
radiographs alone to diagnose CPA; requiring computed 
tomography (CT), which is often unavailable, might delay 
diagnosis. Multiple studies have demonstrated that CT is 
more sensitive than chest radiography for demonstrating 
several features, namely, >1 fungal balls, pulmonary nodules, 
multiple cavities, and disease in the apices and retrocardiac 
space (33). Considering the limited availability of CT in many 
healthcare settings, the radiologic criteria adopted are based 
solely on chest radiograph findings. Where available, CT is 
recommended in the context of clinical and microbiological 
suspicion of CPA with a nondiagnostic chest radiograph.
Fungal Ball or Aspergilloma, Intracavitary Material,  
or Fluid Level on Chest Radiograph
The differential diagnosis for a fungal ball in the lung is 
limited: echinoccocal cyst, necrotizing bronchogenic 
carcinoma, or acute or subacute invasive fungal infection. 
Similar-appearing conditions are lung abscess, Rasmussen 
aneurysm in a tuberculous cavity, cavitating hematoma, or 
lung infarct (34). If single and in a localized area of lung, 
with few or no symptoms, a simple aspergilloma is the 
most precise diagnosis (Figure 1) and can be resected or 
observed without antifungal treatment. Although presence 
of a fungal ball is highly suggestive of an aspergilloma as 
a manifestation of CPA, microbiological confirmation is 
required for a definitive diagnosis.
Occasionally, a fluid level is visible in cavities. Few 
of these cavities have been sampled with aspiration and 
microbiological analysis, but when done, cultures are usually 
positive for A. fumigatus or, less commonly, Staphylococcus 
aureus, Pseudomonas aeruginosa, and other pathogens. 
Therefore, a fluid level in a cavity is entirely consistent with 
CPA but may also represent co-infection (35).
Cavitation
The cardinal feature of CPA is the presence of >1 cavities. 
The cavities may be small or large; may have thick or, 
less commonly, thin walls; and usually abut the pleura 
(33,36). The cavities expand and may coalesce during 
progression of infection. In patients with extensive bullous 
emphysema, inflammation around a bulla may resemble 
cavitation. The differential diagnosis of chronic cavitary 
lesions includes mycobacterial infection, endemic fungal 
infection, and malignancy (37). The cavities seen with CPA 
are often located in the upper lung zone and may mimic 
TB; in patients with NTM infection and endemic fungal 
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diseases, the cavities may be located in any lung zone. 
A distinguishing feature of CPA is slow progression of 
findings over months or years, whereas active pulmonary 
TB infection progresses faster (34,38) (Figure 2). Patients 
with NTM infection may also have cavitary lesions; 
however, lesions are more common among older white 
men with underlying lung disease (39). Patients with 
residual coccidioidal or other infectious cavities are usually 
asymptomatic unless these conditions are complicated by 
aspergilloma or superinfected (40). Cavitary bronchogenic 
carcinoma is usually associated with adenopathy and often 
pleural effusion.
Pleural Thickening
In the pre-CT era, pleural thickening was regarded as 
a sign of aspergilloma; indeed, pleural thickening is 
common in patients with CPA (34,38). For many patients, 
pleural thickening seen on CT images usually consists of 
2 components: fibrosis of the pleura overlying a cavity 
or area of consolidation and indrawing of extrapleural 
fat (typically seen in chronic inflammatory processes of 
the lung). This subtle distinction cannot be made readily 
from a chest radiograph. Pleural thickening should be 
regarded as a common feature of CPA and useful for 
diagnosis. Furthermore, pleural thickening is a specific 
feature of CPA, rarely seen in patients with TB or chronic 
coccidioidal or other fungal cavities (40,41). Tuberculous 
empyema is usually exhibited as a large pleural effusion 
(42) and is commonly accompanied by interlobular 
septal thickening and micronodules (43). Cavitating 
bronchogenic carcinoma may invade the chest wall 
causing bone destruction or may cause diffuse pleural 
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Figure 1. A) Chest radiograph showing aspergilloma (fungal ball) in the left upper lung lobe. B) Axial computed tomography image 
shows increased density in an irregular left apical cavity, a sequela of pulmonary tuberculosis, consistent with an aspergilloma.
Figure 2. Computed tomography images of a patient with chronic pulmonary aspergillosis. A) Left upper lung lobe thick-walled 
cavity, showing associated pleural thickening. B) Same patient several months later, demonstrating progression of cavitation with 
increased pericavitary consolidation and formation of a fungal ball within the cavity. Aspergilloma formation is a late feature of chronic 
pulmonary aspergillosis.
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involvement; however, these manifestations are distinct 
from the focal pleural thickening associated with CPA.
Pericavitary Infiltration
The inflammatory changes seen adjacent to cavities 
in patients with CPA are often marked, reflecting 
inflammation but not hyphal invasion. These areas 
may merge with localized areas of fibrosis, pleural 
thickening, or both but are usually obvious on plain chest 
radiographs (36); they indicate active CPA and are a clear 
indication for therapy (44). Such pericavitary infiltrates, 
unless very extensive, are uncommon in reactivation of 
TB and NTM disease. Pericavitary consolidation 
may be seen in patients with chronic fibrocavitary 
coccidioidomycosis (40).
CT Image Features
One radiologic aspect of CPA not characterized on a chest 
radiograph is the interior of a cavity. Aspergillus grows 
inside the cavity along the wall, resulting in an irregular 
appearance of the inner border seen on CT images. 
In addition, the cavity may contain linear opacities 
representing mats of fungal growth that have detached 
from the cavity wall (38). These growths often merge to 
form sponge-like densities, which can be described as 
a fungal ball containing air (45). These structures may 
detach from the cavity wall and may be mobile. For 
purposes of the definitions outlined in this article, all 
these characteristic features are deemed to be equivalent 
to a fungal ball (Figure 3). With antifungal therapy, they 
resolve more readily than an aspergilloma.
One feature for which CT is much more sensitive than 
chest radiography is the Aspergillus nodule, particularly 
when the nodule is small (46). These nodules may have 
a maximum diameter of 5–50 mm, may be single or 
multiple, and may be solid or have central cavitation. 
Larger nodules (>3 cm) are more accurately described 
as masses, which may also be attributable to Aspergillus 
infection. The differential diagnosis of the Aspergillus 
nodule is broad and includes carcinoma (primary or 
secondary), coccidioidomycosis, cryptococcosis, NTM 
infection, and others.
Establishing a definitive diagnosis of a nodule usually 
requires resection or biopsy, especially because many 
patients do not have elevated IgG against Aspergillus 
or positive sputum cultures (47,48). Because these 
diagnostic procedures are not available in many medical 
centers in lower- and middle-income countries, we elected 
to consider these separately and not include them in our 
operational definition.
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Figure 3. Computed tomography images showing early features of fungal ball formation in pulmonary cavities. A) Two left lower lung lobe 
posterior thick-walled cavities, 1 with a fluid level. B) Two right apical cavities, the larger with an irregular interior wall, most consistent with 
fungal growth. C) Left apex replaced by an irregular thick-walled cavity with multiple areas of fungal growth on the interior surface of the 
cavity. D) Substantial volume loss in the right upper lobe with replacement by a small anterior cavity and larger crescent-shaped cavity with 
both pleural thickening and fat indrawing along the pleural surface posteriorly. The cavity shows marked irregularity consistent with fungal 
growth. E) A right upper lobe thin-walled cavity containing 2 areas of fungal growth, 1 of which has detached from the wall as a thick mat 
of mycelial growth with a larger lump in the cavity interior. F) Multiple cavities in both upper lobes, with wall irregularity in the left upper lobe 
cavity consistent with surface fugal growth. The right upper lobe cavity shows pleural thickening and indrawing of fat posteriorly.
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Culture-Based and Non–Culture-Based  
Evidence of Aspergillosis
The most reliable diagnostic test for CPA is a positive 
Aspergillus antibody test result, indicative of an immune 
response to Aspergillus. The second most reliable 
diagnostic marker for CPA is detection of Aspergillus in 
the airways by use of culture, antigen, and/or nucleic acid 
amplification (PCR).
Antibodies against Aspergillus 
Elevated circulating levels of Aspergillus antibodies are 
present in >95% but <100% of patients (49–51). Most 
commercial assays detect A. fumigatus IgG; however, CPA 
is occasionally caused by other Aspergillus species, resulting 
in false-negative results. In addition, some patients with CPA 
are subtly immunocompromised, as has been documented 
with nonprotective pneumococcal or Haemophilus 
antibodies (52); low circulating CD4 (T helper), CD19 (B 
cell), or CD56 (natural killer) cell counts (53); and poor 
production of gamma interferon interleukin 17A, interleukin 
12, or both (54). Such patients may not mount a detectable 
IgG response. Many patients have detectable A. fumigatus 
IgE and elevated total IgE in the absence of any other 
features of allergic Aspergillus disease (21).
Serologic testing for Aspergillus relies mainly on the 
detection of IgG and of precipitating antibodies (known as 
precipitins), which may be IgG or IgM. Precipitin detection 
requires immunodiffusion and electrophoresis migration 
methods, which lack standardization and are too laborious 
and time-consuming for resource-constrained settings. 
Consequently, we focused on commercially available 
enzyme immunoassay kits that detect IgG. Up to 2015, 
there were few direct comparisons of A. fumigatus serology 
(55), but more recently, several have been published (Table 
2). Crucial to these comparisons is defining the cutoff 
values for each assay. The control groups of patients used 
for such comparisons have included healthy persons or 
those with pulmonary disease without aspergillosis. Few 
data on antibody titer associations with age, HIV status, or 
ethnicity of controls are available. New lateral flow devices 
for Aspergillus antibody detection are in the final stages 
of development and, if their performance is good, could 
greatly facilitate diagnosis. The consensus of the expert 
panel was that any Aspergillus antibody test performance 
had to be at least 90% sensitive and 85% specific.
An elevated level of Aspergillus IgG is consistent with 
several conditions, including Aspergillus rhinosinusitis, 
allergic bronchopulmonary aspergillosis, Aspergillus 
bronchitis (notably in cystic fibrosis and bronchiectasis), 
subacute invasive aspergillosis, recovery from invasive 
aspergillosis, and community-acquired Aspergillus 
pneumonia. Because an elevated level of IgG is highly 
sensitive but not specific for CPA, the diagnosis of CPA 
requires the presence of compatible symptoms and 
radiologic abnormalities.
Respiratory Tract Microscopy and Culture
Microscopy of sputum may show hyphae morphologically 
consistent with Aspergillus spp. If present, this finding is 
most consistent with CPA or Aspergillus tracheobronchitis 
(63). Despite the substantial amount of Aspergillus spp. 
in the cavities of patients with CPA, culture positivity 
from sputum samples is lower than expected (41%–81%) 
and is probably biased toward culture-positive cases 
(21,22,64–67). One reason for this lower sensitivity is the 
inoculation of culture plates with very small volumes of 
sputum (65,68) as is done for bacterial culture. Negative 
cultures might reflect an inability of the fungus to adapt to 
in vitro conditions, despite the apparent ease with which 
environmental contamination occurs in the laboratory.
The merits of positive culture results are substantial, 
notably for identifying the Aspergillus species causing 
infection and enabling susceptibility testing to be 
performed. False-positive cultures do occur as a result 
of laboratory contamination. Although most CPA cases 
are caused by A. fumigatus complex (probably sensu 
stricto), A. niger complex and A. flavus complex and rare 
cases caused by unusual pathogenic species are reported. 
In countries such as India, where A. flavus infection is 
much more common, it is not clear what proportion of 
cases are attributable to non–A. fumigatus species. Most 
triazole-resistant A. fumigatus isolated from patients 
with CPA has arisen while the patient was receiving 
therapy and probably result from large fungal loads or 
low drug exposure (low dose, drug interactions, poor 
bioavailability) (69). Isolates may be resistant or have 
intermediate susceptibility to 1–4 triazoles.
Aspergillus Antigen and β-1,3-D-glucan 
Galactomannan is a detectable carbohydrate antigen 
produced by the growth of Aspergillus spp. Galactomannan 
detection is useful for the diagnosis of invasive aspergillosis 
because it is often detectable in serum and bronchoalveolar 
lavage (BAL) fluid. Because tissue invasion does not 
occur in patients with CPA, galactomannan is not usually 
detectable in serum and is usually detectable in BAL fluid 
only (59,70). This finding is of limited utility in lower- and 
middle-income countries because fiberoptic bronchoscopy 
is infrequently done. Galactomannan is detectable in 
sputum or tracheal secretions/aspirates, but the cutoff for 
positivity is not established (71).
A new simple lateral flow assay for different protein 
antigens specific to A. fumigatus has been commercialized, 
but no data are available on sputum detection or its utility 
for patients with CPA. This assay is unlikely to be useful 
in serum because of antibody masking but may be useful 
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Table 2. Performance of commercially available Aspergillus diagnostic serology tests for CPA* 
Ref. Study population, location Assay† Cutoff Sensitivity, % Specificity, % ROC/AUC (95% CI) 
(56) 28 CPA patients DD, Microgen – 89.3 ND ND 
  Bio-Rad galactomannan GM index >0.5 50 ND ND 
(57) 51 CPA patients, 341 
controls‡ 
Bio-Rad Platelia 
Aspergillus IgG 
10 AU/mL 90.2 89.6 ND 
  Serion/Virion ELISA 
classic Aspergillus IgG 
70 AU/mL 88.8 84.4 ND 
(25) 49 SA patients IBL culture filtrate ELISA ND 99 ND ND 
  Bio-Rad galactomannan GM index >0.5 23 ND ND 
(58) 116 CPA patients Bio-Rad Platelia 
Aspergillus IgG 
10 AU/mL 86 ND ND 
  ThermoFisher Scientific 
ImmunoCAP 
40 mg/L 85 ND ND 
  DD  56 ND ND 
(59) 168 CPA patients Bio-Rad galactomannan GM index >0.5 23 ND 0.538 (0.496–0.580) 
  DD ND 98 ND ND 
(60) 89 CPA patients, 10 
aspergilloma patients, 
212 blood healthy donors 
Aspergillus LDBio 
Western blot IgG kit 
ND CPA, 91.0; 
aspergilloma, 
90.0 
ND ND 
(49) 
 
241 CPA patients, 100 
blood donors, Uganda 
Dynamiker 65 AU/mL 77 97 0.918 (0.89–0.946) 
  Omega (Genesis) 
Aspergillus IgG ELISA 
kit 
20 AU/mL 75 99 0.902 (0.871–0.933) 
  Immulite Siemens 10 mg/L 96 98 0.991 (0.982–1) 
  ThermoFisher Scientific 
Immunocap 
20 mg/L 96 98 0.996 (0.992–1) 
  Serion/Virion ELISA 
classic Aspergillus IgG 
35 AU/mL 90 98 0.973 (0.96–0.987) 
  Precipitins (Microgen) ND 59 100 ND 
(50) 
 
17 SA patients, 62 CPA 
patients, 25 CNPA 
patients, 205 controls§ 
Bordier OD >1 SA, 95.6; CPA, 
97.4; CNPA: 100 
90.3 0.997 (0.962–0.991) 
  Bio-Rad Platelia 
Aspergillus IgG 
10 AU/mL SA, 95.6; CPA, 
97.4; CNPA, 100 
91.3 0.951 (0.928–0.974) 
  Serion/Virion ELISA 
classic Aspergillus IgG 
70 AU/mL SA, 78.3; CPA, 
82.0; CNPA, 
82.9 
81.5 0.897 (0.863–0.931) 
 (51) 51 possible CPA patients, 
96 proven CPA patients, 
122 controls¶ 
ThermoFisher Scientific 
ImmunoCAP 
50 mg/L Possible CPA, 
39.2; proven 
CPA, 97.9 
ND 0.94 (0.912–0.972) 
 (61) 241 CPA patients, 152 
healthy controls, the 
Netherlands 
Siemens Immulite 25 mg/L 92.9 99.3 0.948 (0.921–0.975) 
 241 CPA patients, 141 
healthy controls, Belgium 
ThermoFisher Scientific 
ImmunoCAP 
50 mg/L 83.8 95.6 0.956 (0.937–0.974) 
 241 CPA patients, 222 
healthy controls, France 
Serion 50 U/mL 84.2 91 0.944 (0.925–0.964) 
 118 CPA patients, 222 
healthy controls, France 
Bio-Rad 1.5 AU/mL 93.2 98.2 0.955 (0.922–0.988) 
 (62) 241 CPA patients, 299 
healthy controls, Uganda 
Siemens Immulite 15 mg/L 94.6 98 0.984 (0.972–0.997) 
 241 CPA patients, 398 
patients with treated TB, 
Uganda  
Siemens Immulite 15 mg/L 94.6 94.5 0.972 (0.959–0.985) 
 241 CPA patients, 234 
patients with treated TB, 
radiologically screened for 
CPA, Uganda 
Siemens Immulite 25 mg/L 92.9 98.7 0.979 (0.967–0.992) 
*AU, absorbance units; CPA, chronic pulmonary aspergillosis; CNPA, chronic necrotizing pulmonary aspergillosis; DD, double diffusion (precipitins); GM, 
galactomannan; ND, not determined (did not test enough control serum to assess); OD, optical density; Ref, reference; ROC/AUC, receiver operating 
characteristic/area under the curve; SA, simple aspergilloma; TB, tuberculosis; –, not applicable. 
†Bio-Rad, Marnes-la-Coquette, France; Bordier, Crissier, Switzerland; DD, in-house test (58); Dynamiker, Tianjin, China; IBL, Hamburg, Germany; LDBio 
Diagnostics, Lyon, France; Microgen, Camberley, UK; Omega, Alva, Scotland, UK; Serion/Virion, Würzburg, Germany; Siemens, Camberley, UK; 
ThermoFisher, Uppsala, Switzerland. 
‡Population included 26 patients with Aspergillus bronchial colonization, 44 patients with 1 positive Aspergillus culture considered as colonization, 49 
patients with negative microbiological results, and 222 pregnant women. 
§Control groups comprised 14 patients colonized with Aspergillus and 191 patients with respiratory symptoms. 
¶Possible CPA, Aspergillus precipitin negative and a persistently elevated inflammation marker; proven CPA, Aspergillus precipitin positive and a 
persistently elevated inflammation marker; control, other chronic respiratory disease (any Aspergillus precipitin and temporary elevated inflammation 
marker). 
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Table 3. Final consensus definition of CPA in resource-constrained settings, determined by Global Action Fund for Fungal Infections 
international expert panel* 
Required criteria† Details 
Symptoms for >3 mo Hemoptysis and/or persistent cough, and/or weight loss; other 
symptoms are common, but not required, notably fatigue, chest 
pain, dyspnea, and sputum production 
Radiologic features Progressive cavitation on chest imaging and/or intracavitary  
fungal ball and/or pleural thickening or pericavitary fibrosis  
or infiltrates all adjacent to cavities 
Microbiological evidence of Aspergillus infection Positive Aspergillus-specific IgG and/or sputum microscopy 
results showing hyphae consistent with Aspergillus and/or 
Aspergillus growth on >2 sputum or other respiratory samples 
Mycobacterial infection ruled out with smear, GeneXpert, and/or 
mycobacterial culture‡ 
It is possible for mycobacterial infection and CPA to be present 
concurrently, but this diagnosis requires characteristic radiological 
findings on CT scan that are not present with pulmonary TB 
including pleural thickening, a fungal ball or other intracavitary 
material, or marked pericavitary infiltrates in addition to a positive 
Aspergillus IgG antibody test 
*CPA, chronic pulmonary aspergillosis; CT, computed tomography; TB, tuberculosis. 
†All 4 criteria are required. 
‡GeneXpert (http://www.cepheid.com/us/cepheid-solutions/systems/genexpert-systems/genexpert-iv). 
 
Figure 4. Diagnostic algorithm 
incorporating the chest 
radiographic appearance 
and results of rapid TB 
investigations with the case 
definition of CPA. ABPA, 
allergic bronchopulmonary 
aspergillosis; CPA, chronic 
pulmonary aspergillosis; CT, 
computed tomography; NTM, 
nontuberculous mycobacteria; 
TB, tuberculosis. GeneXpert, 
http://www.cepheid.com/us/
cepheid-solutions/systems/
genexpert-systems/genexpert-iv
ONLINE REPORT
in BAL fluid (72,73). β-1,3-D-glucan is released by 
Aspergillus spp. (and many other fungi) during infection 
but is less specific and probably not more sensitive than 
serum galactomannan in patients with CPA.
Molecular Detection of Aspergillus
For patients with CPA, PCR detection of Aspergillus 
spp. in sputum is significantly more sensitive than 
culture (63). However, the quality and possibly quantity 
of the sputum sample influence PCR performance (71). 
Furthermore, studies have shown that the sensitivity of 
PCR for detection of Aspergillus is ≈80%. Depending on 
the cutoff value used, low specificity may also be an issue. 
Molecular assays for Aspergillus spp. are not routinely 
available in most medical centers worldwide, especially 
in lower- and middle-income countries.
Consensus Definition and Proposed Algorithm
The definition of CPA recommended for use in resource-
constrained settings in shown in Table 3. In a patient who 
has had symptoms consistent with chronic Aspergillus 
infection for >3 months, a chest radiograph should be 
obtained (Figure 4). If a chest radiograph is not possible, 
then pulmonary TB should be excluded by examination of 
respiratory specimens. The chest radiograph appearance 
determines the next course of action. If the chest radiograph 
is not remarkable, the signs and symptoms may be caused by 
bronchiectasis or systemic disease. If the chest radiograph 
shows consolidation without cavitation, then other 
diagnoses such as lung malignancy, airway obstruction, or 
endemic fungal infections should be considered. If the chest 
radiograph shows cavitation, then work-up for possible 
pulmonary TB should be initiated according to national 
practice and standards. A positive result for pulmonary 
TB should lead to appropriate treatment. If the pulmonary 
TB results are negative, and especially if the radiographic 
findings include pleural thickening, fungal ball, or 
pericavitary fibrosis or infiltrates, serum should be tested 
for Aspergillus IgG (Figure 4). If the Aspergillus IgG test 
result is negative (or unavailable), then sputum microscopy 
for hyphae or fungal culture should be performed; yield is 
higher when multiple specimens are tested. If the sputum 
microscopy for hyphae or fungal culture is negative, then 
other diagnoses, such as atypical mycobacterial infection or 
endemic fungal infection, should be considered. If sputum 
microscopy for hyphae or culture is positive, or if a serum 
Aspergillus antibody test result is positive, then CPA is 
confirmed and treatment with itraconazole or voriconazole 
is advised (19).
Conclusions
We present recommendations for diagnosing CPA, adapted 
for clinical use and public health surveillance in resource-
constrained settings. The adapted definition relies on a 
combination of signs and symptoms, chest radiograph 
features, and serologic evidence of Aspergillus infection; 
it is applicable to almost all patient groups in which CPA 
occurs. Prospective evaluation of the proposed definition 
and associated algorithms will be valuable in the contexts 
of different geographic and HIV and pulmonary TB 
burdens (74). We believe that the proposed operational 
definition of CPA in lower- and middle-income countries 
will facilitate advancements in research and practice 
(clinical, laboratory, radiologic, and public health) 
and policy (health services and public health) in these 
countries and globally in resource-constrained settings.
The workshop was funded by the Global Action Fund for 
Fungal Infections. Contributions toward the workshop were 
received from the European Confederation for Medical 
Mycology, European Society for Clinical Microbiology and 
Infectious Diseases, the International Society for Human and 
Animal Mycology, Miravista Diagnostics, Immy Inc., Pfizer 
Inc., Basliea Pharmaceutica, Gilead Sciences, Merck Inc., 
Cidara Therapeutics Inc., Viamet Pharmaceuticals, F2G Ltd., 
Pulmocide Ltd., and Scynexis Inc. Some workshop expenses 
were covered by the National Aspergillosis Centre, University 
Hospital of South Manchester.
D.W.D. and family hold Founder shares in F2G Ltd., a 
University of Manchester spin-out antifungal discovery 
company. D.W.D. acts or has recently acted as a consultant 
to Astellas, Sigma Tau, Basilea, Scynexis, Cidara, Biosergen, 
Quintiles, Pulmatrix, Fujifilm, Zambon, and Pulmocide. 
In the past 3 years, he has been paid for talks on behalf of 
Astellas, Dynamiker, Gilead, Merck, Mylan, and Pfizer. He 
is a longstanding member of the Infectious Disease Society 
of America Aspergillosis Guidelines group, the European 
Society for Clinical Microbiology and Infectious Diseases 
Aspergillosis Guidelines Group, and the British Society for 
Medical Mycology Standards of Care Committee. I.D.P. has 
received research grants, test kit donations, or both from 
Astellas, Siemens, Dynamiker, Serion/Virion, OLM Medical, 
and Genesis. C.M.J. is a consultant to Canon Medical Research 
USA and author of UpToDate, Inc. M.C. has been paid for 
talks on behalf of Astellas, Gilead, and Pfizer. A.A.-I. has 
received grants from Gilead Sciences, Scynexis, and F2G and 
has been paid for talks on behalf of Gilead. P.B. is a cofounder 
of Alergenetica SL and Syngenics Ltd. and has current grant 
support from Medical Research Council, Fungal Infection 
Trust, EU Framework 7, and the National Institutes of Health. 
M.H. has received a research grant from Gilead and served on 
the speakers’ bureau of Gilead, Basilea, and Merck. K.I. has 
received research grants and honoraria from Pfizer Japan Inc., 
MSD K.K., Astellas Pharma Inc., and Dainippon Sumitomo 
Pharma Co. R.O.O. has received honoraria from Pfizer, 
Nigeria. M.D.R. acts as a consultant for Gilead Sciences, MSD, 
e10 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 8, August 2018
Case Definition of Chronic Pulmonary Aspergillosis in Resource-Constrained Settings
Pfizer, Astellas, Basilea, and Pulmocide and is a member of 
the European Society for Clinical Microbiology and Infectious 
Diseases Aspergillosis Guidelines Group. H.J.F.S. received 
honoraria from Chiesi and travel grants from Gilead. C.S. 
has received grants or conference support from the Fungal 
Infection Trust, European Society for Clinical Microbiology 
and Infectious Diseases, and MSD. None of the other authors 
report a conflict of interest.
About the Author 
Dr. Denning, an infectious diseases clinician who is heavily 
involved in postgraduate teaching and lectures worldwide, 
leads LIFE (Leading International Fungal Education) and is 
president of the Global Action Fund for Fungal Infections. His 
primary research interests are chronic and allergic  pulmonary 
fungal diseases, the global burden of fungal infection, and azole 
resistance in Aspergillus.
References
  1. Goodwin RA Jr, Owens FT, Snell JD, Hubbard WW,  
Buchanan RD, Terry RT, et al. Chronic pulmonary  
histoplasmosis. Medicine (Baltimore). 1976;55:413–52.  
http://dx.doi.org/10.1097/00005792-197611000-00001
  2. Shah A, Panjabi C. Allergic bronchopulmonary aspergillosis: 
a review of a disease with a worldwide distribution. J Asthma. 
2002;39:273–89. http://dx.doi.org/10.1081/JAS-120002284
  3. Chong S, Lee KS, Yi CA, Chung MJ, Kim TS, Han J. Pulmonary 
fungal infection: imaging findings in immunocompetent and  
immunocompromised patients. Eur J Radiol. 2006;59:371–83. 
http://dx.doi.org/10.1016/j.ejrad.2006.04.017
  4. Chu HQ, Li B, Zhao L, Huang DD, Zhang ZM, Xu JF, et al. Chest 
imaging comparison between non-tuberculous and tuberculosis 
mycobacteria in sputum acid fast bacilli smear-positive patients. 
Eur Rev Med Pharmacol Sci. 2015;19:2429–39.
  5. Chiang CY, Yu MC, Yang SL, Yen MY, Bai KJ. Surveillance  
of tuberculosis in Taipei: the influence of nontuberculous  
mycobacteria. PLoS One. 2015;10:e0142324. http://dx.doi.org/ 
10.1371/journal.pone.0142324
  6. Getahun H, Harrington M, O’Brien R, Nunn P. Diagnosis of  
smear-negative pulmonary tuberculosis in people with HIV  
infection or AIDS in resource-constrained settings: informing 
urgent policy changes. Lancet. 2007;369:2042–9. http://dx.doi.org/ 
10.1016/S0140-6736(07)60284-0
  7. Schweer KE, Bangard C, Hekmat K, Cornely OA. Chronic  
pulmonary aspergillosis. Mycoses. 2014;57:257–70.  
http://dx.doi.org/10.1111/myc.12152
  8. Pasipanodya JG, Miller TL, Vecino M, Munguia G, Bae S, 
Drewyer G, et al. Using the St. George respiratory questionnaire 
to ascertain health quality in persons with treated pulmonary 
tuberculosis. Chest. 2007;132:1591–8. http://dx.doi.org/10.1378/
chest.07-0755
  9. Denning DW, Pleuvry A, Cole DC. Global burden of chronic 
pulmonary aspergillosis as a sequel to pulmonary tuberculosis. Bull 
World Health Organ. 2011;89:864–72. http://dx.doi.org/10.2471/
BLT.11.089441
10. Chakaya J, Kirenga B, Getahun H. Long term complications after 
completion of pulmonary tuberculosis treatment: a quest for a 
public health approach. J Clin TB Mycobact Dis 2016;3:10–12.
11. World Health Organization. 2015 Global Tuberculosis Report. 
Geneva: The Organization; 2015. 
12. Hargreaves NJ, Kadzakumanja O, Phiri S, Lee CH, Tang X,  
Salaniponi FM, et al. Pneumocystis carinii pneumonia in patients 
being registered for smear-negative pulmonary tuberculosis in 
Malawi. Trans R Soc Trop Med Hyg. 2001;95:402–8.  
http://dx.doi.org/10.1016/S0035-9203(01)90197-X
13.  Nakiyingi L, Ssengooba W, Nakanjako D, Armstrong D,  
Holshouser M, Kirenga BJ, et al. Predictors and outcomes of 
mycobacteremia among HIV-infected smear-negative presumptive 
tuberculosis patients in Uganda. BMC Infect Dis 2015;15:62.
14. Pohl C, Jugheli L, Haraka F, Mfinanga E, Said K, Reither K.  
Pulmonary aspergilloma: a treatment challenge in sub-Saharan  
Africa. PLoS Negl Trop Dis. 2013;7:e2352. http://dx.doi.org/ 
10.1371/journal.pntd.0002352
15. British Tuberculosis Association. Aspergillus in persistent lung 
cavities after tuberculosis. A report from the Research Committee 
of the British Tuberculosis Association. Tubercle. 1968;49:1–11. 
http://dx.doi.org/10.1016/S0041-3879(68)80002-9
16. Smith NL, Denning DW. Underlying conditions in chronic  
pulmonary aspergillosis including simple aspergilloma.  
Eur Respir J. 2011;37:865–72. http://dx.doi.org/10.1183/ 
09031936.00054810
17. The Lancet Respiratory Medicine. Chronic pulmonary aspergillosis:  
help is on the way. Lancet Respir Med 2016;4:83.
18. Patterson TF, Thompson GR III, Denning DW, Fishman JA,  
Hadley S, Herbrecht R, et al. Practice guidelines for the diagnosis 
and management of aspergillosis: 2016 update by the Infectious 
Diseases Society of America. Clin Infect Dis. 2016;63:e1–60. 
http://dx.doi.org/10.1093/cid/ciw326
19. Denning DW, Cadranel J, Beigelman-Aubry C, Ader F,  
Chakrabarti A, Blot S, et al.; European Society for Clinical  
Microbiology and Infectious Diseases and European Respira-
tory Society. Chronic pulmonary aspergillosis: rationale and 
clinical guidelines for diagnosis and management. Eur Respir J. 
2016;47:45–68. http://dx.doi.org/10.1183/13993003.00583-2015
20. Kohno S, Tamura K, Niki Y, Izumikawa K, Oka S, Ogawa K,  
et al. Executive summary of Japanese Domestic Guidelines 
for Management of Deep-seated Mycosis 2014. Med Mycol J. 
2016;57:E117–63. http://dx.doi.org/10.3314/mmj.16-00010
21. Denning DW, Riniotis K, Dobrashian R, Sambatakou H. Chronic 
cavitary and fibrosing pulmonary and pleural aspergillosis: case 
series, proposed nomenclature change, and review. Clin Infect Dis. 
2003;37(Suppl 3):S265–80. http://dx.doi.org/10.1086/376526
22. Kohno S, Izumikawa K, Ogawa K, Kurashima A, Okimoto N,  
Amitani R, et al.; Japan Chronic Pulmonary Aspergillosis Study 
Group (JCPASG). Intravenous micafungin versus voriconazole for 
chronic pulmonary aspergillosis: a multicenter trial in Japan.  
J Infect. 2010;61:410–8. http://dx.doi.org/10.1016/j.jinf.2010.08.005
23. Cadranel J, Philippe B, Hennequin C, Bergeron A, Bergot E, 
Bourdin A, et al. Voriconazole for chronic pulmonary aspergillosis: 
a prospective multicenter trial. Eur J Clin Microbiol Infect Dis. 
2012;31:3231–9. http://dx.doi.org/10.1007/s10096-012-1690-y
24. Ohba H, Miwa S, Shirai M, Kanai M, Eifuku T, Suda T, et al.  
Clinical characteristics and prognosis of chronic pulmonary  
aspergillosis. Respir Med. 2012;106:724–9. http://dx.doi.org/ 
10.1016/j.rmed.2012.01.014
25. Jhun BW, Jeon K, Eom JS, Lee JH, Suh GY, Kwon OJ, et al.  
Clinical characteristics and treatment outcomes of chronic  
pulmonary aspergillosis. Med Mycol. 2013;51:811–7.  
http://dx.doi.org/10.3109/13693786.2013.806826
26. Kosmidis C, Denning DW. The clinical spectrum of pulmonary 
aspergillosis. Thorax. 2015;70:270–7. http://dx.doi.org/10.1136/
thoraxjnl-2014-206291
27. Pasqualotto AC, editor. Aspergillosis: from diagnosis to prevention. 
1st ed. New York: Springer; 2010.
28. Tomlinson JR, Sahn SA. Aspergilloma in sarcoid and tuberculosis. 
Chest. 1987;92:505–8. http://dx.doi.org/10.1378/chest.92.3.505
 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 8, August 2018 e11
ONLINE REPORT
29. Camara B, Reymond E, Saint-Raymond C, Roth H,  
Brenier-Pinchart MP, Pinel C, et al.; Grenoble Aspergillus  
Committee. Characteristics and outcomes of chronic pulmonary 
aspergillosis: a retrospective analysis of a tertiary hospital registry. 
Clin Respir J. 2015;9:65–73. http://dx.doi.org/10.1111/crj.12105
30.  Salzer HJ, Cornely OA. Awareness of predictors of mortality may 
help improve outcome in chronic pulmonary aspergillosis. Eur 
Respir J. 2017;49:2.
31. Salzer HJ, Heyckendorf J, Kalsdorf B, Rolling T, Lange C. 
Characterization of patients with chronic pulmonary aspergillosis 
according to the new ESCMID/ERS/ECMM and IDSA  
guidelines. Mycoses. 2017;60:136–42. http://dx.doi.org/10.1111/
myc.12589
32. Farid S, Mohamed S, Devbhandari M, Kneale M, Richardson M, 
Soon SY, et al. Results of surgery for chronic pulmonary  
aspergillosis, optimal antifungal therapy and proposed high risk 
factors for recurrence—a national centre’s experience.  
J Cardiothorac Surg. 2013;8:180. http://dx.doi.org/10.1186/ 
1749-8090-8-180
33. Desai SR, Hedayati V, Patel K, Hansell DM. Chronic aspergillosis 
of the lungs: unravelling the terminology and radiology. Eur Radiol. 
2015;25:3100–7. http://dx.doi.org/10.1007/s00330-015-3690-7
34. Franquet T, Müller NL, Giménez A, Guembe P, de La Torre J, 
Bagué S. Spectrum of pulmonary aspergillosis: histologic,  
clinical, and radiologic findings. Radiographics. 2001;21:825–37. 
http://dx.doi.org/10.1148/radiographics.21.4.g01jl03825
35. Denning DW. Chronic forms of pulmonary aspergillosis.  
Clin Microbiol Infect. 2001;7(Suppl 2):25–31.  
http://dx.doi.org/10.1111/j.1469-0691.2001.tb00006.x
36. Greene R. The radiological spectrum of pulmonary  
aspergillosis. Med Mycol. 2005;43(Suppl 1):S147–54.  
http://dx.doi.org/10.1080/13693780500064771
37. Gadkowski LB, Stout JE. Cavitary pulmonary disease.  
Clin Microbiol Rev. 2008; 21:305–33. http://dx.doi.org/10.1128/
CMR.00060-07
38. Gotway MB, Dawn SK, Caoili EM, Reddy GP, Araoz PA,  
Webb WR. The radiologic spectrum of pulmonary aspergillus 
infections. J Comput Assist Tomogr. 2002;26:159–73.  
http://dx.doi.org/10.1097/00004728-200203000-00001
39. Martinez S, McAdams HP, Batchu CS. The many faces of  
pulmonary nontuberculous mycobacterial infection. AJR Am 
J Roentgenol. 2007;189:177–86. http://dx.doi.org/10.2214/
AJR.07.2074
40. Jude CM, Nayak NB, Patel MK, Deshmukh M, Batra P.  
Pulmonary coccidioidomycosis: pictorial review of chest  
radiographic and CT findings. Radiographics. 2014;34:912–25. 
http://dx.doi.org/10.1148/rg.344130134
41. Jeong YJ, Lee KS. Pulmonary tuberculosis: up-to-date imaging  
and management. AJR Am J Roentgenol. 2008;191:834–44.  
http://dx.doi.org/10.2214/AJR.07.3896
42. McAdams HP, Erasmus J, Winter JA. Radiologic manifestations  
of pulmonary tuberculosis. Radiol Clin North Am. 1995; 
33:655–78.
43. Ko JM, Park HJ, Cho DG, Kim CH. CT differentiation of tuber-
culous and non-tuberculous pleural infection, with emphasis on 
pulmonary changes. Int J Tuberc Lung Dis. 2015;19:1361–8. http://
dx.doi.org/ 10.5588/ijtld.15.0092
44. Izumikawa K, Ohtsu Y, Kawabata M, Takaya H, Miyamoto A, 
Sakamoto S, et al. Clinical efficacy of micafungin for chronic 
pulmonary aspergillosis. Med Mycol. 2007;45:273–8.  
http://dx.doi.org/10.1080/13693780701278386
45. Roberts CM, Citron KM, Strickland B. Intrathoracic aspergilloma: 
role of CT in diagnosis and treatment. Radiology. 1987;165:123–8. 
http://dx.doi.org/10.1148/radiology.165.1.3628758
46. Muldoon EG, Sharman A, Page I, Bishop P, Denning DW.  
Aspergillus nodules; another presentation of chronic pulmonary  
aspergillosis. BMC Pulm Med 2016;16:123. http://dx.doi.org/ 
10.1186/s12890-016-0276-3
47. Muniappan A, Tapias LF, Butala P, Wain JC, Wright CD,  
Donahue DM, et al. Surgical therapy of pulmonary aspergillomas:  
a 30-year North American experience. Ann Thorac Surg. 
2014;97:432–8. http://dx.doi.org/10.1016/j.athoracsur.2013.10.050
48. Reischies F, Hoenigl M. The role of surgical debridement in  
different clinical manifestations of invasive aspergillosis. Mycoses. 
2014;57(Suppl 2):1–14. http://dx.doi.org/10.1111/myc.12224
49. Page ID, Richardson MD, Denning DW. Comparison of six 
Aspergillus-specific IgG assays for the diagnosis of chronic  
pulmonary aspergillosis (CPA). J Infect. 2016;72:240–9.  
http://dx.doi.org/10.1016/j.jinf.2015.11.003
50. Dumollard C, Bailly S, Perriot S, Brenier-Pinchart MP,  
Saint-Raymond C, Camara B, et al. Prospective evaluation of a 
new aspergillus IgG enzyme immunoassay kit for diagnosis of 
chronic and allergic pulmonary aspergillosis. J Clin Microbiol. 
2016;54:1236–42. http://dx.doi.org/10.1128/JCM.03261-15
51. Fujiuchi S, Fujita Y, Suzuki H, Doushita K, Kuroda H,  
Takahashi M, et al. Evaluation of a quantitative serological assay 
for diagnosing chronic pulmonary aspergillosis. J Clin Microbiol. 
2016;54:1496–9. http://dx.doi.org/10.1128/JCM.01475-15
52. Kosmidis C, Powell G, Borrow R, Morris J, Alachkar H,  
Denning DW. Response to pneumococcal polysaccharide  
vaccination in patients with chronic and allergic aspergillosis.  
Vaccine. 2015;33:7271–5. http://dx.doi.org/10.1016/ 
j.vaccine.2015.10.114
53. Bongomin F, Harris C, Foden P, Kosmidis C, Denning DW. Innate 
and adaptive immune defects in chronic pulmonary aspergillosis.  
J Fungi (Basel). 2017;3:26. http://dx.doi.org/10.3390/jof3020026
54. Döffinger R, Harris C, Lear S, Newton P, Alachkar H,  
Dinakantha S, et al. Impaired Th1 and Th17 immunity in chronic 
pulmonary aspergillosis. In: Proceedings of the 6th Advances 
against Aspergillosis. 6th Advances against Aspergillosis  
Conference; Feb 27–Mar 1, 2014; Madrid, Spain [cited 2018 May 
23]. http://www.advancesagainstaspergillosis.org/2014/index.htm
55. Page ID, Richardson M, Denning DW. Antibody testing in  
aspergillosis—quo vadis? Med Mycol. 2015;53:417–39.  
http://dx.doi.org/10.1093/mmy/myv020
56. Kitasato Y, Tao Y, Hoshino T, Tachibana K, Inoshima N,  
Yoshida M, et al. Comparison of Aspergillus galactomannan  
antigen testing with a new cut-off index and Aspergillus  
precipitating antibody testing for the diagnosis of chronic  
pulmonary aspergillosis. Respirology. 2009;14:701–8.  
http://dx.doi.org/10.1111/j.1440-1843.2009.01548.x
57. Guitard J, Sendid B, Thorez S, Gits M, Hennequin C. Evaluation  
of a recombinant antigen-based enzyme immunoassay for the  
diagnosis of noninvasive aspergillosis. J Clin Microbiol. 
2012;50:762–5. http://dx.doi.org/10.1128/JCM.01257-11
58. Baxter CG, Denning DW, Jones AM, Todd A, Moore CB, Richard-
son MD. Performance of two Aspergillus IgG EIA  
assays compared with the precipitin test in chronic and allergic  
aspergillosis. Clin Microbiol Infect. 2013;19:E197–204.  
http://dx.doi.org/10.1111/1469-0691.12133
59. Shin B, Koh WJ, Jeong BH, Yoo H, Park HY, Suh GY, et al.  
Serum galactomannan antigen test for the diagnosis of chronic 
pulmonary aspergillosis. J Infect. 2014;68:494–9. http://dx.doi.org/ 
10.1016/j.jinf.2014.01.005
60. Oliva A, Flori P, Hennequin C, Dubus JC, Reynaud-Gaubert M,  
Charpin D, et al. Evaluation of the Aspergillus Western blot 
IgG kit for diagnosis of chronic aspergillosis. J Clin Microbiol. 
2015;53:248–54. http://dx.doi.org/10.1128/JCM.02690-14
61. Page ID, Baxter C, Hennequin C, Richardson MD,  
van Hoeyveld E, van Toorenenbergen AW, et al. Receiver  
operating characteristic curve analysis of four Aspergillus-specific 
IgG assays for the diagnosis of chronic pulmonary aspergillosis.  
e12 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 8, August 2018
Case Definition of Chronic Pulmonary Aspergillosis in Resource-Constrained Settings
Diagn Microbiol Infect Dis. 2018;91:47–51. http://dx.doi.org/ 
10.1016/j.diagmicrobio.2018.01.001
62. Page ID, Richardson MD, van Toorenenbergen A, Denning DW. 
Siemens Immulite Aspergillus-specific IgG assay for chronic  
pulmonary aspergillosis diagnosis. Med Mycol. 2018 [cited 2018 
May 25]. https://doi.org/10.1093/mmy/myy024
63. Langridge PJ, Sheehan RL, Denning DW. Microbial yield from 
physiotherapy assisted sputum production in respiratory  
outpatients. BMC Pulm Med. 2016;6:23. http://dx.doi.org/10.1186/
s12890-016-0188-2
64. Nam HS, Jeon K, Um SW, Suh GY, Chung MP, Kim H, et al.  
Clinical characteristics and treatment outcomes of chronic  
necrotizing pulmonary aspergillosis: a review of 43 cases.  
Int J Infect Dis. 2010;14:e479–82. http://dx.doi.org/10.1016/ 
j.ijid.2009.07.011
65. Fraczek MG, Kirwan MB, Moore CB, Morris J, Denning DW, 
Richardson MD. Volume dependency for culture of fungi from 
respiratory secretions and increased sensitivity of Aspergillus  
quantitative PCR. Mycoses. 2014;57:69–78. http://dx.doi.org/ 
10.1111/myc.12103
66. Camuset J, Nunes H, Dombret MC, Bergeron A, Henno P,  
Philippe B, et al. Treatment of chronic pulmonary aspergillosis 
by voriconazole in nonimmunocompromised patients. Chest. 
2007;131:1435–41. http://dx.doi.org/10.1378/chest.06-2441
67. Cucchetto G, Cazzadori A, Conti M, Cascio GL, Braggio P,  
Concia E. Treatment of chronic pulmonary aspergillosis with  
voriconazole: review of a case series. Infection. 2015;43:277–86. 
http://dx.doi.org/10.1007/s15010-014-0711-4
68. Pashley CH, Fairs A, Morley JP, Tailor S, Agbetile J, Bafadhel M,  
et al. Routine processing procedures for isolating filamentous 
fungi from respiratory sputum samples may underestimate fungal 
prevalence. Med Mycol. 2012;50:433–8. http://dx.doi.org/10.3109/
13693786.2011.615762
69. Howard SJ, Cerar D, Anderson MJ, Albarrag A, Fisher MC, 
Pasqualotto AC, et al. Frequency and evolution of azole resistance  
in Aspergillus fumigatus associated with treatment failure. 
Emerg Infect Dis. 2009;15:1068–76. http://dx.doi.org/10.3201/
eid1507.090043
70. Izumikawa K, Yamamoto Y, Mihara T, Takazono T, Morinaga Y,  
Kurihara S, et al. Bronchoalveolar lavage galactomannan for 
the diagnosis of chronic pulmonary aspergillosis. Med Mycol. 
2012;50:811–7. http://dx.doi.org/10.3109/13693786.2012.682228
71. Fayemiwo S, Moore CB, Foden P, Denning DW, Richardson MD.  
Comparative performance of Aspergillus galactomannan ELISA 
and PCR in sputum from patients with ABPA and CPA.  
J Microbiol Methods. 2017;140:32–9. http://dx.doi.org/10.1016/ 
j.mimet.2017.06.016
72. Prattes J, Flick H, Prüller F, Koidl C, Raggam RB, Palfner M,  
et al. Novel tests for diagnosis of invasive aspergillosis in patients 
with underlying respiratory diseases. Am J Respir Crit Care Med. 
2014;190:922–9. http://dx.doi.org/10.1164/rccm.201407-1275OC
73. Eigl S, Prattes J, Lackner M, Willinger B, Spiess B, Reinwald M,  
et al. Multicenter evaluation of a lateral-flow device test for  
diagnosing invasive pulmonary aspergillosis in ICU patients. Crit 
Care. 2015;9:178. http://dx.doi.org/10.1186/s13054-015-0905-x
74.  Godet C, Alastruey-Izquierdo A, Flick H, Hennequin C,  
Mikilps-Mikgelbs R, Munteanu O, et al.; CPAnet. A CPAnet 
consensus statement on research priorities for chronic pulmonary 
aspergillosis: a neglected fungal infection that requires attention.  
J Antimicrob Chemother. 2018;73:280–6. http://dx.doi.org/10.1093/
jac/dkx390
Address for correspondence: David W. Denning, National Aspergillosis 
Centre, University Hospital of South Manchester, Southmoor Rd, 
Manchester M23 9LT, UK; email: ddenning@manchester.ac.uk
 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 8, August 2018 e13
EID SPOTLIGHT 
TOPIC
http://wwwnc.cdc.gov/eid/
page/world-tb-day
Tuberculosis
World TB Day, on March 24th each year, is designed 
to build public awareness that tuberculosis today 
remains an epidemic in much of the world, causing 
the deaths of nearly 1.5 million people each year, 
mostly in developing countries. It commemorates 
the day in 1882 when Dr. Robert Koch astounded 
the scientific community by announcing that he 
had discovered the cause of tuberculosis, the 
TB bacillus. At the time of Koch’s announcement 
in Berlin, TB was raging through Europe and the 
Americas, causing the death of one out of every 
seven people. Koch’s discovery opened the way 
toward diagnosing and curing TB.
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